Recently, Jiangsu Academy of Science and Technology for Development released the list of "Top 100 Innovative Enterprises in Jiangsu Province 2020". Hansoh Pharma successfully made the list, ranked 17th, once again demonstrating its innovative strength. This is also the second consecutive year for the company to be on the list. 

Hansoh Pharma Ranked Top 20 Among "Top 100 Innovative Enterprises in Jiangsu Province 2020" 

01 Harness technology as the engine, and stay concentrated, focused, and professional to innovate for health

Focusing on innovation is the core element of Hansoh Pharma's high-quality development. As a Chinese pharmaceutical company with a history of 26 years, Hansoh Pharma keeps improving its R&D capability and core competitiveness through technological innovation to serve the health and well-being of the people. 

Hansoh Pharma has been engaged in the pharmaceutical industry for more than 20 years. Pharmaceutical innovation is a high-investment, high-risk and long-term cause. Upholding the mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma has adopted an innovation-led approach since its establishment, and has risen up to the challenge by building core competitiveness through leading technology. Hansoh Pharma has intensified efforts to combat major diseases. Over the years, Hansoh Pharma has been striving to address unmet clinical needs in the treatment of major diseases, particularly oncology, CNS diseases, anti-infectives and diabetes, and is committed to bringing better disease solutions to patients and improving drug accessibility. Hansoh Pharma has built an efficient R&D system. To build efficient and sustainable R&D innovation capability, Hansoh Pharma has established R&D centers in Shanghai, Lianyungang, etc., continuously increased investment in R&D year by year, set up a number of leading R&D platforms and mastered a number of proprietary technologies, trained and engaged high-level technical talents at home and abroad, accelerated the cultivation of innovative talents, and formed a first-class R&D team led by high-end talents as well as master and doctoral degree holders. 

02 Promote development through innovation and reap fruitful results

With continuous strides forward in R&D, Hansoh Pharma's innovation-driven transition has entered the harvest period. Up to March 2021, four Class 1 innovative drugs have been approved for marketing: Ameile (Almonertinib Mesilate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets), Fulaimei (Polyethylene Glycol Loxenatide Injection), and Mailingda (Morinidazole and Sodium Chloride Injection). So far, the company has nearly 20 innovative drugs in various clinical stages, and the Class 1 innovative drug Amibufenamide 𓄧for hepatitis B is expected to be approved for marketing in the first half of this year.

 

China's first original third-generation EGFR-TKI Ameile (Almonertinib Mesilate Tablets) 

Specifically, Ameile is China's first original third-generation EGFR-TKI, for the treatment of NSCLC; second-line data show that patients' mPFS (median progressio🌼n-free survival) exceeds one year, the only of its kind in the world. The first-line clinical study of Ameile has reached its endpoint with positive results and the data is expected to be announced at this year's international academic forum. In July 2020, the company entered into a strategic collaboration with EQRx, according to which EQRx will lead the clinical development and commercialization activities of Ameile in Europe, the United States, Japan, and even other parts of the world, bringing the benefits of China's original drugs to patients worldwide.

 This year marks the beginning of the 14th Five-Year Plan, and innovation throughout the industry has become the general trend. In the future, Hansoh Pharma will continue to maintain the innovation momentum, continuously increase R&D investment to enhance innovation capability, explore the road of independent innovation for Chinese pharmaceutical companies, and take practical actions to help implement the Healthy China 2030 strategy.